Maine passes law regulating pharmacy benefit managers.
Lebrikizumab Demonstrates Sustained Response for Atopic Dermatitis at 3 Years
The ADjoin long-term extensive study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.
Dispensing Leadership: Defining Your Philosophy
Join Shawn Bjorndal, PharmD, RPh, and Jesse McCullough, PharmD, for the first episode of Dispensing Leadership, a new podcast from Drug Topics® and RPhAlly.
Biosimilar Ustekinumab-Kfce Shows Equivalence to Stelara
Investigators report that the safety profile is also similar between both drugs.
How Barbershops Are Becoming Community Health Care Destinations
The Cut Hypertension Program operates in barbershops across the Bay Area in California. The program’s lead pharmacist joined us to discuss main themes and goals of the new initiative.
STEADY Intervention Improves Mental Health Outcomes for Diabetes, Disordered Eating
The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.
New Interventions Needed to Improve Rate of Pharmacy No-Shows
Clinical pharmacists were asked to provide interventions to improve their patients’ rate of not showing up to a pharmacy appointment.
